scholarly journals Glycated proteins in infant formula may cause inflammation that could disturb tolerance induction and lead to autoimmune disease

2019 ◽  
Vol 108 (10) ◽  
pp. 1744-1746 ◽  
Author(s):  
Charlotte Erlanson‐Albertsson ◽  
Mona Landin‐Olsson
Keyword(s):  
Autoimmune Disease ◽  
Infant Formula ◽  
Tolerance Induction ◽  
Glycated Proteins

scholarly journals Peptide Characterization and Functional Stability of a Partially Hydrolyzed Whey-Based Formula over Time

Nutrients ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 3011
Author(s):  
Tristan Bourdeau ◽  
Michael Affolter ◽  
Lénaïck Dupuis ◽  
Alexandre Panchaud ◽  
Sabine Lahrichi ◽  
...  
Keyword(s):  
Infant Formula ◽  
Oral Tolerance ◽  
Allergic Sensitization ◽  
Tolerance Induction ◽  
Specific Ige ◽  
Size Exclusion ◽  
Preclinical Model ◽  
Meta Analyses ◽  
Oral Tolerance Induction ◽  
Over Time

Human clinical trials have shown that a specific partially hydrolyzed 100% whey-based infant formula (pHF-W) reduces AD risk in the first yeast of life. Meta-analyses with a specific pHF-W (pHF-W1) confirm a protective effect while other meta-analyses pooling different pHF-W show conflicting results. Here we investigated the molecular composition and functional properties of the specific pHF-W1 as well as the stability of its manufacturing process over time. This specific pHF-W1 was compared with other pHF-Ws. We used size exclusion chromatography to characterize the peptide molecular weight (MW), a rat basophil degranulation assay to assess the relative level of beta-lactoglobulin (BLG) allergenicity and a preclinical model of oral tolerance induction to test prevention of allergic sensitization. To analyze the exact peptide sequences before and after an HLA binding assay, a mass cytometry approach was used. Peptide size allergenicity and oral tolerance induction were conserved across pHF-W1 batches of production and time. The median MW of the 37 samples of pHF-W1 tested was 800 ± 400 Da. Further oral tolerance induction was observed using 10 different batches of the pHF-W1 with a mean reduction of BLG-specific IgE levels of 0.76 log (95% CI = −0.95; −0.57). When comparing pHF-W1 with three other formulas (pHF-W2 3 and 4), peptide size was not necessarily associated with allergenicity reduction in vitro nor oral tolerance induction in vivo as measured by specific IgE level (p < 0.05 for pHF-W1 and 2 and p = 0.271 and p = 0.189 for pHF-W3 and 4 respectively). Peptide composition showed a limited overlap between the formulas tested ranging from 11.7% to 24.2%. Furthermore nine regions in the BLG sequence were identified as binding HLA-DR. In conclusion, not all pHF-Ws tested have the same peptide size distribution decreased allergenicity and ability to induce oral tolerance. Specific peptides are released during the different processes used by different infant formula producers.

scholarly journals Myeloid-derived suppressor cells mediate tolerance induction in autoimmune disease

Immunology ◽  
2017 ◽  
Vol 151 (1) ◽  
pp. 26-42 ◽  
Author(s):  
Anja Wegner ◽  
Johan Verhagen ◽  
David C. Wraith
Keyword(s):  
Autoimmune Disease ◽  
Tolerance Induction ◽  
Suppressor Cells ◽  
Myeloid Derived Suppressor Cells

scholarly journals Therapeutic administration of Tregitope-Human Albumin Fusion with Insulin Peptides to promote Antigen-Specific Adaptive Tolerance Induction

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Anne S. De Groot ◽  
Gail Skowron ◽  
James Robert White ◽  
Christine Boyle ◽  
Guilhem Richard ◽  
...  
Keyword(s):  
T Cell ◽  
Autoimmune Disease ◽  
Islet Cells ◽  
Tolerance Induction ◽  
Nod Mice ◽  
Human Albumin ◽  
Target Antigen ◽  
T Cell Epitopes ◽  
Effector Cells ◽  
T Effector Cells

Abstract Type 1 Diabetes (T1D) is an autoimmune disease that is associated with effector T cell (Teff) destruction of insulin-producing pancreatic beta-islet cells. Among the therapies being evaluated for T1D is the restoration of regulatory T cell (Treg) activity, specifically directed toward down-modulation of beta-islet antigen-specific T effector cells. This is also known as antigen-specific adaptive tolerance induction for T1D (T1D ASATI). Tregitopes (T regulatory cell epitopes) are natural T cell epitopes derived from immunoglobulin G (IgG) that were identified in 2008 and have been evaluated in several autoimmune disease models. In the T1D ASATI studies presented here, Tregitope peptides were administered to non-obese diabetic (NOD) mice at the onset of diabetes within two clinically-relevant delivery systems (liposomes and in human serum albumin [HSA]-fusion products) in combination with preproinsulin (PPI) target antigen peptides. The combination of Tregitope-albumin fusions and PPI peptides reduced the incidence of severe diabetes and reversed mild diabetes, over 49 days of treatment and observation. Combining HSA-Tregitope fusions with PPI peptides is a promising ASATI approach for therapy of T1D.

A role for plasma cell targeting agents in immune tolerance induction in autoimmune disease and antibody responses to therapeutic proteins

2016 ◽  
Vol 165 ◽  
pp. 55-59 ◽  
Author(s):  
A.S. Rosenberg ◽  
A.R. Pariser ◽  
B. Diamond ◽  
L. Yao ◽  
L.A. Turka ◽  
...  
Keyword(s):  
Autoimmune Disease ◽  
Plasma Cell ◽  
Immune Tolerance ◽  
Therapeutic Proteins ◽  
Tolerance Induction ◽  
Antibody Responses ◽  
Cell Targeting ◽  
Immune Tolerance Induction

Recombinant lactobacillus strains secreting myelin antigens for mucosal tolerance induction in autoimmune disease

1998 ◽  
Vol 90 (1) ◽  
pp. 82
Author(s):  
K. Maassen ◽  
C. van Holten ◽  
R. Leer ◽  
J. Laman ◽  
W. Boersma ◽  
...  
Keyword(s):  
Autoimmune Disease ◽  
Tolerance Induction ◽  
Mucosal Tolerance ◽  
Myelin Antigens

Antigen-Specific Tolerance Induction and the Immunotherapy of Experimental Autoimmune Disease

2007 ◽  
pp. 120-136 ◽  
Author(s):  
S. M. Anderton ◽  
C. Burkhart ◽  
G. Y. Liu ◽  
B. Metzler ◽  
D. C. Wraith
Keyword(s):  
Autoimmune Disease ◽  
Tolerance Induction ◽  
Specific Tolerance ◽  
Experimental Autoimmune

Anti–CD3 Antibody Treatment: a Promising Immunotherapeutic for Type 1 Diabetes

2016 ◽  
Vol 1 (01) ◽  
Author(s):  
Riyasat Ali ◽  
Sudhir Kumar
Keyword(s):  
Type 1 Diabetes ◽  
Autoimmune Disease ◽  
Pancreatic Beta Cells ◽  
Tolerance Induction ◽  
Peripheral Tolerance ◽  
Major Goal ◽  
Antibody Treatment ◽  
Current Scenario ◽  
Preclinical And Clinical Studies

Type 1 diabetes (T1D) is an autoimmune disease characterized by spontaneous pancreatic beta cells destruction. The central cause of T1D is mainly the weakening of central and peripheral tolerance. So, the induction of tolerance is a major goal for most of the immunotherapies. Investigations over the last couple of decades have shown that anti–CD3 monoclonal antibodies (mAbs) and their therapeutic variants effectively treat autoimmune disease in animal models, and have also shown promise in clinical trials. Tolerance induction by anti–CD3 mAbs is mainly related to the induction of Th2 type immune response and regulatory T cells (Tregs) development that control pathogenic autoimmune responses. Here, we review main findings of last couple of decades research, and current scenario of anti–CD3 mediated immune tolerance, and preclinical and clinical studies in which anti–CD3 mAbs have been used.

Laryngeal Manifestations of Autoimmune Diseases

2020 ◽  
Vol 5 (2) ◽  
pp. 439-456
Author(s):  
Jenny L. Pierce
Keyword(s):  
Autoimmune Disease ◽  
Autoimmune Diseases ◽  
Patient Outcomes ◽  
Correct Diagnosis ◽  
Upper Airway ◽  
Clinical Implications ◽  
Laryngeal Function ◽  
The Past ◽  
Referral Practices ◽  
Timely Referral

Purpose This review article provides an overview of autoimmune diseases and their effects on voice and laryngeal function. Method A literature review was conducted in PubMed. Combinations of the following keywords were used: “autoimmune disease and upper airway,” “larynx,” “cough,” “voice,” “dysphonia,” and “dyspnea.” Precedence was given to articles published in the past 10 years due to recent advances in this area and to review articles. Ultimately, 115 articles were included for review. Results Approximately 81 autoimmune diseases exist, with 18 of those highlighted in the literature as having laryngeal involvement. The general and laryngeal manifestations of these 18 are discussed in detail, in addition to the clinical implications for a laryngeal expert. Conclusions Voice, breathing, and cough symptoms may be an indication of underlying autoimmune disease. However, these symptoms are often similar to those in the general population. Appropriate differential diagnosis and timely referral practices maximize patient outcomes. Guidelines are provided to facilitate correct diagnosis when an autoimmune disease is suspected.

Are pharyngeal pouches a manifestation of autoimmune disease?

1998 ◽  
Vol 23 (3) ◽  
pp. 284-284
Author(s):  
Oko ◽  
Swan ◽  
Bottazzo ◽  
Collins
Keyword(s):  
Autoimmune Disease

Mechanisms of tolerance induction after rat liver transplantation: Intrahepatic CD4+T cells produce different cytokines during rejection and tolerance in response to stimulation

2001 ◽  
Vol 120 (5) ◽  
pp. A346-A346
Author(s):  
H GASSEL ◽  
J KAUCZOK ◽  
C OTTO ◽  
U STEGER ◽  
W TIMMERMANN ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
T Cells ◽  
Rat Liver ◽  
Cd4 T Cells ◽  
Tolerance Induction ◽  
Rat Liver Transplantation
Sign in / Sign up

Export Citation Format

Share Document